{"log_id": 2886664957157521780, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 1e-05, "average": 0.997753, "min": 0.990617}, "location": {"width": 152, "top": 159, "height": 26, "left": 156}, "words": "碱联用时应谨慎"}, {"probability": {"variance": 0.004647, "average": 0.978048, "min": 0.681636}, "location": {"width": 781, "top": 190, "height": 32, "left": 198}, "words": "尚无非布司他与其他通过XO代谢的药物(如硫唑嘌呤、巯嘌呤)相互作用的研究"}, {"probability": {"variance": 0.001286, "average": 0.991409, "min": 0.781805}, "location": {"width": 844, "top": 228, "height": 31, "left": 156}, "words": "由非布司他引起的XO抑制可能会提高这些药物在血浆中的浓度,从而导致中毒。因此非"}, {"probability": {"variance": 0.000149, "average": 0.992556, "min": 0.954609}, "location": {"width": 496, "top": 267, "height": 28, "left": 156}, "words": "布司他禁用于正在接受硫唑嘌呤或巯嘌呤治疗的患者"}, {"probability": {"variance": 0.004776, "average": 0.976265, "min": 0.768953}, "location": {"width": 210, "top": 305, "height": 27, "left": 195}, "words": "2.细胞毒类化疗药物"}, {"probability": {"variance": 1e-05, "average": 0.997557, "min": 0.984799}, "location": {"width": 803, "top": 340, "height": 30, "left": 198}, "words": "未进行非布司他与细胞毒类化疗药物的相互作用研究。用细胞毒类药物化疗期间使"}, {"probability": {"variance": 3.1e-05, "average": 0.994479, "min": 0.981974}, "location": {"width": 286, "top": 379, "height": 30, "left": 155}, "words": "用非布司他的安全性数据未知"}, {"probability": {"variance": 0.000967, "average": 0.989948, "min": 0.886848}, "location": {"width": 252, "top": 415, "height": 28, "left": 195}, "words": "3.体内药物相互作用研究"}, {"probability": {"variance": 0.000912, "average": 0.989222, "min": 0.831305}, "location": {"width": 802, "top": 449, "height": 33, "left": 197}, "words": "基于在健康受试者体内进行的药物相互作用研究,非布司他与秋水仙碱、萘普生、吲"}, {"probability": {"variance": 0.0001, "average": 0.995421, "min": 0.94242}, "location": {"width": 845, "top": 485, "height": 32, "left": 155}, "words": "哚美辛、氢氯噻嗪、华法林、地昔帕明合用时无显著相互作用。因此,非布司他可与这些"}, {"probability": {"variance": 5e-06, "average": 0.997868, "min": 0.99391}, "location": {"width": 88, "top": 527, "height": 27, "left": 156}, "words": "药物联用"}, {"probability": {"variance": 5e-06, "average": 0.997677, "min": 0.993141}, "location": {"width": 118, "top": 562, "height": 28, "left": 161}, "words": "【药物过量】"}, {"probability": {"variance": 2e-05, "average": 0.997056, "min": 0.981383}, "location": {"width": 804, "top": 597, "height": 31, "left": 197}, "words": "对健康受试者的研究表明,在连续服用300mg/d的非布司他7天时未发现剂量限制性"}, {"probability": {"variance": 4.1e-05, "average": 0.996601, "min": 0.970105}, "location": {"width": 845, "top": 633, "height": 32, "left": 155}, "words": "毒性。临床研究中尚无本品过量的报道。如病人服用本品过量应接受对症治疗以及支持疗"}, {"probability": {"variance": 0, "average": 0.997059, "min": 0.997059}, "location": {"width": 28, "top": 675, "height": 25, "left": 153}, "words": "法"}, {"probability": {"variance": 0.000865, "average": 0.984214, "min": 0.918665}, "location": {"width": 116, "top": 709, "height": 28, "left": 161}, "words": "【药理毒理】"}, {"probability": {"variance": 0.002039, "average": 0.973045, "min": 0.894841}, "location": {"width": 87, "top": 746, "height": 25, "left": 199}, "words": "药理作用"}, {"probability": {"variance": 0.000554, "average": 0.991945, "min": 0.855341}, "location": {"width": 804, "top": 779, "height": 30, "left": 198}, "words": "非布司他为2芳基噻唑衍生物,是一种黄嘌呤氧化酶抑制剂,通过抑制尿酸合成降低"}, {"probability": {"variance": 0.001306, "average": 0.986663, "min": 0.843047}, "location": {"width": 810, "top": 815, "height": 32, "left": 156}, "words": "血清尿酸浓度。非布司他常规治疗浓度下不会抑制其他参与嘌呤和嘧啶合成与代谢的酶"}, {"probability": {"variance": 5.2e-05, "average": 0.994453, "min": 0.984292}, "location": {"width": 164, "top": 856, "height": 33, "left": 196}, "words": "药效学"}, {"probability": {"variance": 0.000112, "average": 0.995129, "min": 0.953718}, "location": {"width": 804, "top": 889, "height": 30, "left": 197}, "words": "对尿酸和黄嘌呤浓度的影响:健康受试者服用非布司他后,24小时平均血清尿酸浓度"}, {"probability": {"variance": 7.9e-05, "average": 0.996758, "min": 0.94519}, "location": {"width": 845, "top": 928, "height": 31, "left": 156}, "words": "出现剂量依赖性降低,黄嘌呤的血清平均浓度升高。此外,尿酸的每日总排泄量减少。同"}, {"probability": {"variance": 0.002402, "average": 0.989149, "min": 0.673127}, "location": {"width": 845, "top": 965, "height": 30, "left": 155}, "words": "时,每目尿液中的黄嘌呤总排泄量增多。非布司他每日给药量为40mg和80mg时,24小时"}, {"probability": {"variance": 1.2e-05, "average": 0.997404, "min": 0.990537}, "location": {"width": 378, "top": 1004, "height": 27, "left": 156}, "words": "平均血清尿酸浓度的降低率为40%55%"}, {"probability": {"variance": 3e-05, "average": 0.997361, "min": 0.968786}, "location": {"width": 802, "top": 1040, "height": 28, "left": 198}, "words": "对心脏复极化的影响:分别以健康受试者和痛风患者为试验对象进行试验,通过测定"}, {"probability": {"variance": 5.4e-05, "average": 0.994978, "min": 0.970644}, "location": {"width": 845, "top": 1076, "height": 29, "left": 157}, "words": "QTc间期评估本品对心脏复极化的影响。本品每日最高剂量达300mg,稳态时对QTc间期"}, {"probability": {"variance": 0, "average": 0.99979, "min": 0.99958}, "location": {"width": 67, "top": 1116, "height": 25, "left": 156}, "words": "无影响"}, {"probability": {"variance": 2e-06, "average": 0.998569, "min": 0.99612}, "location": {"width": 88, "top": 1152, "height": 26, "left": 198}, "words": "毒理研究"}, {"probability": {"variance": 2.4e-05, "average": 0.996043, "min": 0.980788}, "location": {"width": 804, "top": 1185, "height": 30, "left": 198}, "words": "重复给药毒性:在12个月 Beagle犬毒性试验中,剂量为15mg/kg剂量时(约为人用剂"}, {"probability": {"variance": 0.000739, "average": 0.991681, "min": 0.827114}, "location": {"width": 845, "top": 1222, "height": 34, "left": 155}, "words": "量80mg/d时血浆暴露量的4倍)在肾脏中有黄嘌呤结晶沉淀及结石。类似的情况也出现在"}, {"probability": {"variance": 0.000384, "average": 0.992684, "min": 0.874249}, "location": {"width": 845, "top": 1261, "height": 30, "left": 156}, "words": "大鼠6个月试验中,在48mg/kg(约为人用剂量80mg/d时血浆暴露量的35倍)剂量时有黄"}, {"probability": {"variance": 0.021689, "average": 0.929955, "min": 0.600715}, "location": {"width": 129, "top": 1301, "height": 26, "left": 157}, "words": "嘌呤结晶沉淀"}, {"probability": {"variance": 0.000943, "average": 0.985843, "min": 0.866453}, "location": {"width": 803, "top": 1335, "height": 31, "left": 198}, "words": "遗传毒性:非布司他在有或无代谢活化时,CHL细胞染色体畸变试验结果阳性。非布"}, {"probability": {"variance": 0.002153, "average": 0.985699, "min": 0.697109}, "location": {"width": 844, "top": 1372, "height": 33, "left": 158}, "words": "司他Ames试验、人外周血淋巴细胞染色体畸变试验、L5178Y小鼠淋巴瘤细胞染色体畸变"}, {"probability": {"variance": 0.000119, "average": 0.994664, "min": 0.94851}, "location": {"width": 822, "top": 1408, "height": 36, "left": 158}, "words": "试验、小鼠微核试验、大鼠程序外DNA合成试验、大鼠骨髓细胞微核试验结果均为阴性"}, {"probability": {"variance": 0.001151, "average": 0.987588, "min": 0.798693}, "location": {"width": 804, "top": 1449, "height": 29, "left": 199}, "words": "生殖毒性:非布司他经口给药剂量达48mg/kg/d(约为人用剂量80mg/d时血浆暴露量"}, {"probability": {"variance": 0.000171, "average": 0.992773, "min": 0.942749}, "location": {"width": 545, "top": 1487, "height": 30, "left": 158}, "words": "的35倍)时,对雄雌大鼠生育力和生殖行为未见明显影响"}, {"probability": {"variance": 0.000417, "average": 0.991204, "min": 0.899277}, "location": {"width": 804, "top": 1524, "height": 31, "left": 199}, "words": "妊娠大鼠与家兔器官形成期经口给予非布司他剂量达到48mg/kg(约为人用剂量80mg/d"}, {"probability": {"variance": 0.004734, "average": 0.983545, "min": 0.533085}, "location": {"width": 846, "top": 1563, "height": 29, "left": 157}, "words": "时血浆暴露量40-51倍),未见致畸作用。妊娠大鼠围产期经口给予48mg/kg(约为人用剂"}], "language": 3}